Lucid Diagnostics Inc.

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

Current securities

1. 10-Q filingNov 12, 2026
2. Results of Operations and Financial Condition · Regulation FD DisclosureNov 12, 2026
3. Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 22, 2026
4. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingOct 16, 2026
5. Regulation FD DisclosureSep 22, 2026